"using Uni as an argument for how RXPC will lose the rights of Onko-Sure to them. "
That never was, and is not now, my argument.
My argument is this:
* IF UNI and Radient completed that agreement, UNI can manufacture and sell onko-sure while only paying Radient $100,000 per year - no additional royalties.
* IF you are correct, and the agreement was never completed, UNI cannot manufacture and sell onko-sure until Radient's patent expires.
* EITHER WAY, on June 3rd, 2014, when Radient's patent for onko-sure expires, UNI Pharma can manufacture and sell onko-sure in Asia without paying Radient anything. IF the agreement was completed, it terminates on that day.
